One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009;102(2):56–61. doi:10.1258/jrsm.2009.080298
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33(Suppl 1):1–21. doi:10.1038/s41433-018-0300-3
   PubMed Web of Science ®Google Scholar
• Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and extend treatment interval patterns with anti-VEGF therapy in namd patients. Vision. 2019;3(3). doi:10.3390/vision3030041
   Google Scholar
• Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin Z. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(21). doi:10.3390/ijms21218242
   Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and harrier: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for Neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and harrier: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular Age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
   PubMed Web of Science ®Google Scholar
• Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122(9):1837–1845. doi:10.1016/j.ophtha.2015.05.010
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Karcher H, Andersen S, Souied EH. Anti-VEGF treatment discontinuation and interval in neovascular age-related macular degeneration in the US. Am J Ophthalmol. 2022;242:189–196. doi:10.1016/j.ajo.2022.06.005
   PubMed Web of Science ®Google Scholar
• Sobolewska B, Sabsabi M, Ziemssen F. Importance of treatment duration: unmasking barriers and discovering the reasons for undertreatment of anti-VEGF agents in neovascular age-related macular degeneration. Clin Ophthalmol. 2021;15:4317–4326. doi:10.2147/OPTH.S325763
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet. 2013;382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–1867. doi:10.2147/DDDT.S97653
   PubMed Web of Science ®Google Scholar
• Baumal CR, Sorensen TL, Karcher H, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol. 2022;101(2):123–139. doi:10.1111/aos.15242
   PubMed Web of Science ®Google Scholar
• Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758. doi:10.3390/jcm10132758
   PubMed Web of Science ®Google Scholar
• Bulirsch LM, Sassmannshausen M, Nadal J, Leigl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2022;106(9):1288–1294. doi:10.1136/bjophthalmol-2020-318672
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Havilio M, Syntosi A, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35(11):2983–2990. doi:10.1038/s41433-020-01354-4
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye. 2020;34(12):2249–2256. doi:10.1038/s41433-020-0799-y
   PubMed Web of Science ®Google Scholar
• Granstam E, Aurell S, Sjovall K, Paul A. Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2085–2093. doi:10.1007/s00417-020-05059-y
   PubMed Web of Science ®Google Scholar
• MacCumber MW, Yu JS, Sagkriotis A, et al. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Can J Ophthalmol. 2021;58(3):252–261. doi:10.1016/j.jcjo.2021.10.008
   PubMedGoogle Scholar
• Rave V, Sharma K, Wagner A, Kapoor K. Real-world analysis of brolucizumab in neovascular AMD. Investig Ophthalmol Vis Sci. 2021;62(8):431.
   Web of Science ®Google Scholar
• Walter SD, Saba NJ. Real-world efficacy and safety of brolucizumab. Investig Ophthalmol Vis Sci. 2021;62(8):456.
   Web of Science ®Google Scholar
• European Medicines Agency. Brolucizumab SmPC; 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/beovu. Accessed January 10, 2023.
   Google Scholar
• US Food and Drug Administration. Beovu USPI. FDA; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf. Accessed January 10, 2023.
   Google Scholar
• Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with nAMD and persistent retinal fluid. Ophthalmology. 2022;129(9):974–985. doi:10.1016/j.ophtha.2022.04.028
   PubMed Web of Science ®Google Scholar
• Coney JM, Zubricky R, Sinha SB, et al. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. Int J Retin Vitr. 2023;9(8). doi:10.1186/s40942-023-00445-0
   PubMedGoogle Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046–1050. doi:10.1097/IAE.0b013e3181d87e04
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12(1):8195. doi:10.1038/s41598-022-10578-1
   PubMed Web of Science ®Google Scholar
• Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and komodo healthcare map. JAMA Ophthalmol. 2022;140(1):20–28. doi:10.1001/jamaophthalmol.2021.4585
   PubMed Web of Science ®Google Scholar
• Robertson JA, Abdulaal M, Moore MT, et al. Risk and assessment of covid-19 in a retina ophthalmologic setting. Investig Ophthalmol Vis Sci. 2021;62(8):1989.
   Web of Science ®Google Scholar
• Kishimoto MM, Miki A, Chubachi A, et al. One-year results of switching to brolucizumab in exudative age related macular degeneration. Investig Ophthalmol Vis Sci. 2022;63:323–F0154.
   Web of Science ®Google Scholar
• Liegl RG, Karcher H, Chetty-Mhlanga S, Igwe F, Freitas R. The treatment patterns with brolucizumab in Germany (realize) study: a retrospective cohort study based on longitudinal prescription data. Ophthalmol Ther. 2022;12(1):195–208. doi:10.1007/s40123-022-00596-7
   PubMed Web of Science ®Google Scholar